1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,147 | 0,159 | 17.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.04. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 298 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 95 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen | |
| 27.03. | VIVA BIOTECH (01873): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 27.03. | VIVA BIOTECH (01873): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT ON THE PASSING OF U.S. FDA ON-SITE INSPECTION BY LANGHUA PHARMACEUTICAL, A WHOLLY-OWNED SUBSIDIARY | 1 | HKEx | ||
| 27.03. | VIVA BIOTECH (01873): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 3 | HKEx | ||
| 17.03. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 1 | HKEx | ||
| 13.03. | VIVA BIOTECH (01873): POSITIVE PROFIT ALERT | 2 | HKEx | ||
| 16.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 06.01. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 23.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 11.12.24 | Viva Biotech Establishes New Branch in Boston | 3 | Contract Pharma | ||
| 11.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 11.12.24 | Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion | 336 | PR Newswire | HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in... ► Artikel lesen | |
| 02.12.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 14.11.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 06.11.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 30.10.24 | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURNS | - | HKEx |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,050 | -0,20 % | Valneva: Fast sensationell! | News von Trading-Treff.de Valneva hat einen hohen Verlust hinnehmen müssen. Die Aktie verlor gestern am Markt 6,66 %. Damit ist der Titel auch noch (teils) für sehr kurze Zeit unter die Marke von drei... ► Artikel lesen | |
| NOVONESIS | 55,72 | +0,76 % | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | ||
| GENMAB | 174,40 | +0,29 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,618 | -5,62 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| BEIGENE LTD ADR | 202,00 | -0,98 % | BEIGENE (06160): DATE OF FIRST QUARTER 2025 FINANCIAL RESULTS ANNOUNCEMENT AND NOTICE OF AUDIT COMMITTEE ACTION | ||
| MOLECULIN BIOTECH | 0,735 | -100,00 % | Moleculin Biotech, Inc. - 10-K/A, Annual Report | ||
| SINO BIOPHARM | 0,405 | -0,69 % | Kurs von Sino Biopharmaceutical steigt etwas (0,4449 €) | Am Aktienmarkt liegt die Aktie von Sino Biopharmaceutical derzeit im Plus. Zuletzt zahlten Investoren für das Papier 0,44 Euro. Eine Verteuerung in Höhe von 1 Cent erfreut derzeit die Aktionäre von... ► Artikel lesen | |
| VERICEL | 36,200 | +2,26 % | Vericel Corp - 8-K, Current Report | ||
| SENSEI BIOTHERAPEUTICS | 0,337 | -5,07 % | Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress | - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate... ► Artikel lesen | |
| ZAI LAB LTD ADR | 26,000 | +2,36 % | ZAI LAB (09688): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | ||
| BIOXCEL THERAPEUTICS | 1,365 | -100,00 % | BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia | Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash following closing of recent equity financing... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,638 | -6,18 % | MustGrow Biologics Corp.: MustGrow Adds New Biostimulants and Inoculants to Canadian Product Portfolio | Saskatoon, Saskatchewan--(Newsfile Corp. - April 1, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative... ► Artikel lesen | |
| REGENXBIO | 5,250 | 0,00 % | Regenxbio Aktie: Überschaubare Aussichten | Regenxbio verzeichnet aktuell einen Kursrückgang von 3,45 Prozent auf 7,00 Euro, wobei die Aktie in den letzten sieben Tagen sogar über 13 Prozent an Wert eingebüßt hat. Das Unternehmen hat kürzlich... ► Artikel lesen | |
| AKEBIA | 1,880 | +3,98 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa | CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,272 | -2,16 % | CSTONE PHARMA-B (02616): (I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP |
VIVA BIOTECH HOLDINGS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,148 Euro und damit +1,37 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.
